Ajooni Biotech Limited has informed the Exchange about General Updates
AJOONI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Ajooni Biotech reported Q1 FY26 revenue from operations of ₹31.27 crores, up about 22% from ₹25.66 crores in Q1 FY25. Total income for the quarter was ₹31.91 crores versus ₹25.70 crores a year ago. Net profit rose sharply to ₹78.14 lakhs from ₹46.82 lakhs in Q1 FY25, a jump of roughly 67%. Basic and diluted EPS stood at ₹0.02, lower than ₹0.03 in the year-ago quarter, despite higher absolute profit. The company also submitted a balance sheet showing total assets of ₹99.93 crores and equity of ₹88.86 crores as on 30 June 2025. The auditor, Narinder Kumar and Company, issued a clean limited review report with no qualifications or observations.
Strong YoY growth in both revenue and profit is a positive signal for the business, although overall margins remain thin and EPS dipped due to a higher share base. With a clean auditor review, the results are likely already priced in and should not trigger a major stock reaction.